GCP
AUPH icon

GSA Capital Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

GSA Capital Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-103,467
Closed -$1.53M – 1745
2026
Q1 		$1.53M Sell
103,467
-28,481
-22% -$416K 0.1% 271
2025
Q4 		$2.1M Buy
131,948
+120,484
+1,051% +$1.71M 0.18% 70
2025
Q3 		$127K Sell
11,464
-267,954
-96% -$2.93M 0.01% 1502
2025
Q2 		$2.37M Buy
279,418
+190,507
+214% +$1.53M 0.17% 85
2025
Q1 		$715K Buy
88,911
+77,153
+656% +$625K 0.06% 553
2024
Q4 		$106K Sell
11,758
-113,887
-91% -$929K 0.01% 1507
2024
Q3 		$921K Sell
125,645
-102,373
-45% -$635K 0.07% 522
2024
Q2 		$1.3M Sell
228,018
-121,186
-35% -$638K 0.09% 342
2024
Q1 		$1.75M Buy
349,204
+231,260
+196% +$1.57M 0.14% 158
2023
Q4 		$1.06M Buy
+117,944
New +$971K 0.09% 360
2023
Q3 		– Sell
-168,595
Closed -$1.63M – 1488
2023
Q2 		$1.63M Buy
+168,595
New +$1.75M 0.16% 113
2021
Q4 		– Sell
-22,904
Closed -$507K – 1404
2021
Q3 		$507K Buy
+22,904
New +$363K 0.05% 687

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSA Capital Partners's AUPH Position: Q2 2026 in Review

GSA Capital Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2026, closing a stake of 103,467 shares — an estimated $1.53M sold.

GSA Capital Partners first reported a position in AUPH in Q3 2021 and held it in 12 quarters. The position peaked at $2.37M in Q2 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • GSA Capital Partners reported no remaining Aurinia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 103,467 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $1.53M.
  • GSA Capital Partners first reported a position in Aurinia Pharmaceuticals in Q3 2021 and held it in 12 quarters.
  • GSA Capital Partners's Aurinia Pharmaceuticals position peaked at $2.37M in Q2 2025.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.